Cefsulodin is a third-generation cephalosporin antibiotic that is active against Pseudomonas aeruginosa and was discovered by Takeda Pharmaceutical Company in 1977.[1][2][3][4]
TAP Pharmaceuticals had a new drug application on file with FDA for cefsulodin under the brand name Cefonomil as of 1985.[5]
Cefsulodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for Yersinia microorganisms.[6] This agar is most often used in water and beverage testing.[citation needed]
Susceptibility data
The following represents MIC susceptibility data for various P. aeruginosa strains:[7]
- Pseudomonas aeruginosa PA13 (resistant strain): 32 μg/ml
- Pseudomonas aeruginosa (wild-type, susceptible): 4 - 8 μg/ml
References
- ^ "TOKU-E Technical Application Sheet" (PDF). Archived from the original (PDF) on 27 September 2011.
- ^ Smith BR (1984). "Cefsulodin and ceftazidime, two antipseudomonal cephalosporins". Clinical Pharmacy. 3 (4): 373–85. PMID 6380902.
- ^ Neu HC, Scully BE (1984). "Activity of cefsulodin and other agents against Pseudomonas aeruginosa". Reviews of Infectious Diseases. 6 (Suppl 3): S667–77. doi:10.1093/clinids/6.supplement_3.s667. PMID 6443768.
- ^ Wright DB (November 1986). "Cefsulodin". Drug Intelligence & Clinical Pharmacy. 20 (11): 845–9. doi:10.1177/106002808602001104. PMID 3536385. S2CID 243377437.
- ^ "Lupron Is First Abbott-Takeda Product to Reach U.S. Market". Pink Sheet. 15 April 1985.
- ^ "BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar". Food and Drug Administration. Retrieved 2 September 2012.
- ^ "Cefsulodin | the Antimicrobial Index Knowledgebase - TOKU-E".